BPG is committed to discovery and dissemination of knowledge
Articles in Press
2/11/2026 9:16:12 AM | Browse: 3 | Download: 0
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Beyond fibrosis: The imperative for dual steatosis and fibrosis assessment in chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease co-pathology
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Francesco Giangregorio, Elisa Civaschi, Samanta Mazzocchi, Davide Romano, Paolo Clini, Esther Centenara, Umberto Casale and Davide Catucci |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Francesco Giangregorio, Associate Professor, Chief Physician, Director, Department of Internal Medicine, Val Tidone Hospital, Viale II Giugno 1, Castel San Giovanni 29015, Emilia-Romagna, Italy. f.giangregorio67@gmail.com |
| Key Words |
Chronic hepatitis B; Metabolic dysfunction-associated steatotic liver disease; Liver fibrosis; Non-invasive tests; Transforming growth factor-β; L59 (LAP degradation product); Platelet count; Fibrogenesis |
| Core Tip |
Non-invasive assessment of liver injury in chronic hepatitis B is evolving beyond static fibrosis markers toward biologically driven models. The L59-based nomogram proposed by Dai et al captures active fibrogenesis through transforming growth factor-βactivation, integrating molecular, inflammatory, and hematologic parameters. This approach is particularly relevant in patients with concurrent metabolic dysfunction-associated steatotic liver disease, where steatosis may be deceptively mild despite advanced fibrosis. A dual, non-invasive evaluation of fibrosis and steatosis is therefore essential to avoid underestimation of disease severity and to optimize risk stratification in dual-etiology liver disease. |
| Citation |
Giangregorio F, Civaschi E, Mazzocchi S, Romano D, Clini P, Centenara E, Casale U, Catucci D. Beyond fibrosis: The imperative for dual steatosis and fibrosis assessment in chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease co-pathology. World J Hepatol 2026; In press |
 |
Received |
|
2026-01-12 01:47 |
 |
Peer-Review Started |
|
2026-01-12 01:47 |
 |
First Decision by Editorial Office Director |
|
2026-01-16 06:48 |
 |
Return for Revision |
|
2026-01-16 06:48 |
 |
Revised |
|
2026-01-20 22:10 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2026-02-11 02:36 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2026-02-11 09:16 |
 |
Articles in Press |
|
2026-02-11 09:16 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345